Biotechnology in the Time of COVID-19: Commentaries from the Front Line

by Jeremy M. Levin

SARS-CoV-2’s mutation rate suggests that each successive vaccine will need to account for future variants of the virus in the same way that flu vaccines attempt to address the emergence of new variants each season.